NSPXD Projected Dividend Yield
Rebus Holdings Inc ( OTCBB : NSPXD )Inspyr Therapeutics is a clinical-stage, pre-revenue, pharmaceutical company primarily focused on the development of therapeutics for the treatment of diseases. Through its wholly owned subsidiary, Lewis & Clark Pharmaceuticals, Inc., Co. is focusing on a pipeline of small molecule adenosine receptor modulators. The adenosine receptor modulators include A2B antagonists, dual A2A/A2B antagonists, and A2A agonists that have development applicability including indications within immuno-oncology and inflammation. Adenosine is implicated in immunosuppression in the tumor microenvironment. Adenosine also has anti-inflammatory properties in the acute and chronic setting. 20 YEAR PERFORMANCE RESULTS |
NSPXD Dividend History Detail NSPXD Dividend News NSPXD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |